Travere Therapeutics, Inc. (TVTX) Cash Flow Statement
Where TVTX’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- $37.8M
- Capital expenditures
- $58.2M 11.9% of revenue
- Free cash flow
- −$20.4M −4.2% margin
- Returned to shareholders
- —
- Change in cash
- $34.5M cash at year-end $93.0M
Cash from operations
$37.8M
Capital expenditures
−$58.2M
Investments (net)
+$86.5M
Acquisitions & other
−$404,000
Net borrowing (repayment)
−$68.9M
Other financing
+$35.4M
Currency & other
+$2.3M
Change in cash
$34.5M
Drawn to scale: where the cash came from and how it was used. Hover for values.
TVTX operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
TVTX cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$1.6M2016 | $37.8M2025 | — | |
| Capital expenditures | $11.9M2016 | $58.2M2025 | +19.3%/yr | |
| Free cash flow | −$13.5M2016 | −$20.4M2025 | — | |
| Free cash flow margin | −10.1%2016 | −4.2%2025 | +6.0 pts | |
| Stock-based compensation | $29.1M2016 | $44.9M2025 | +4.9%/yr | |
| Share buybacks (net) | $02020 | $02022 | — | |
| Capex / revenue | 8.9%2016 | 11.9%2025 | +2.9 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
TVTX cash flow by activity
OperatingInvestingFinancingChange in cash
TVTX net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
TVTX cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$25.5M | −$320.6M | −$376.3M | −$331.5M | −$217.3M | −$169.4M | −$146.4M | −$102.7M | −$59.7M | −$47.9M |
| Depreciation & amortization | $60.7M | $43.6M | $38.5M | $20.7M | $12.7M | $24.6M | $20.4M | $18.7M | $17.8M | $16.1M |
| Stock-based compensation | $44.9M | $36.9M | $44.2M | $38.1M | $29.6M | $23.6M | $21.1M | $19.8M | $26.9M | $29.1M |
| Change in working capital | −$14.0M | −$63.0M | −$25.5M | $875,000 | $80.8M | −$26.0M | $2.6M | $11.1M | $3.8M | $5.5M |
| Other non-cash items | −$28.3M | $65.7M | $39.0M | $85.4M | $79.4M | $104.5M | $44.1M | $28.2M | $18.6M | −$4.4M |
| Cash from operating activities | $37.8M | −$237.5M | −$280.0M | −$186.3M | −$14.8M | −$42.7M | −$58.2M | −$25.0M | $7.4M | −$1.6M |
| Investing activities | ||||||||||
| Capital expenditures | −$58.2M | −$101.2M | −$41.6M | −$28.4M | −$24.2M | −$119.8M | −$15.6M | −$19.7M | −$14.0M | −$11.9M |
| Investments (net) | $86.5M | $99.3M | $36.0M | −$3.4M | −$113.5M | $58.5M | $35.4M | −$183.6M | $12.1M | — |
| Acquisitions & other investing | −$404,000 | $101.2M | $61.3M | −$791,000 | $0 | $0 | $0 | $0 | $47.5M | $22.3M |
| Cash from investing activities | $27.9M | $99.3M | $55.8M | −$32.6M | −$137.6M | −$61.3M | $19.9M | −$203.3M | $45.6M | $10.4M |
| Financing activities | ||||||||||
| Share repurchases & issuance (net) | — | — | — | $27.1M | $2.1M | $2.0M | — | — | — | — |
| Net borrowing (repayment) | −$68.9M | $0 | $0 | $95.0M | $104.9M | $104.9M | $104.9M | $235.8M | $235.8M | — |
| Shares issued | $0 | $134.7M | $191.2M | $19.5M | $224.9M | $131.5M | $0 | $0 | $0 | $0 |
| Other financing | $35.4M | $4.7M | $27.6M | −$24.1M | −$100.3M | −$110.8M | −$107.0M | −$3.9M | −$230.4M | −$5.7M |
| Cash from financing activities | −$33.5M | $139.4M | $218.8M | $117.6M | $231.7M | $127.7M | −$2.1M | $231.9M | $5.4M | −$5.7M |
| Summary | ||||||||||
| Net change in cash | $34.5M | $359,000 | −$3.5M | −$104.1M | $81.0M | $22.3M | −$40.4M | $3.5M | $58.4M | $3.2M |
| Cash at end of period | $93.0M | $58.5M | $58.2M | $61.7M | $165.8M | $84.8M | $62.4M | $102.9M | $99.4M | $41.0M |
| Free cash flow | −$20.4M | −$338.7M | −$321.6M | −$214.7M | −$38.9M | −$162.6M | −$73.8M | −$44.7M | −$6.6M | −$13.5M |
| Free cash flow margin | −4.2% | −145.3% | −221.4% | −196.1% | −29.5% | −82.0% | −42.1% | −27.2% | −4.3% | −10.1% |
| Capex / revenue | 11.9% | 43.4% | 28.6% | 25.9% | 18.3% | 60.4% | 8.9% | 12.0% | 9.0% | 8.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$34.8M | −$36.6M | −$22.0M | $25.7M | −$12.8M | −$41.2M | −$60.3M | −$54.8M | −$69.7M | −$136.1M | −$88.6M | −$89.2M |
| Depreciation & amortization | $4.2M | $25.2M | $18.1M | $15.8M | $14.0M | $12.8M | $12.1M | $11.2M | $10.3M | $9.9M | $11.9M | $11.5M |
| Stock-based compensation | $21.8M | $16.1M | $11.5M | $11.3M | $10.6M | $11.5M | $9.2M | $8.0M | $9.9M | $9.8M | $8.1M | $11.3M |
| Change in working capital | $49.7M | −$45.1M | $52.7M | −$37.3M | −$5.6M | −$23.7M | $7.4M | −$6.7M | −$60.7M | −$2.9M | $7.1M | −$4.9M |
| Other non-cash items | $17.1M | −$4,000 | $397,000 | −$1.1M | −$1.3M | −$1.6M | −$4.2M | −$278,000 | $69.9M | $364,000 | −$9.0M | $12.2M |
| Cash from operating activities | $58.1M | −$40.4M | $60.7M | $14.3M | $5.0M | −$42.2M | −$35.7M | −$42.5M | −$40.2M | −$119.0M | −$70.5M | −$59.1M |
| Investing activities | ||||||||||||
| Capital expenditures | −$22.2M | −$22.2M | −$18.9M | −$140,000 | −$235,000 | −$11.8M | −$9.6M | −$8.2M | −$12.0M | −$6.5M | −$5.5M | −$10,000 |
| Investments (net) | −$185.2M | $43.7M | −$85.5M | $86.6M | $4.8M | $41.3M | −$80.3M | $46.1M | $28.6M | $104.9M | −$16.9M | $133.3M |
| Acquisitions & other investing | $1.1M | $0 | −$470,000 | $140,000 | $235,000 | $11.8M | $9.6M | $8.2M | $12.0M | $6.5M | $5.5M | $10,000 |
| Cash from investing activities | −$206.3M | $21.5M | −$104.8M | $86.6M | $4.8M | $41.3M | −$80.3M | $46.1M | $28.6M | $104.9M | −$16.9M | $133.3M |
| Financing activities | ||||||||||||
| Net borrowing (repayment) | — | — | $0 | −$68.9M | — | — | — | — | — | — | — | — |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $134.7M | $0 | $0 | $0 | $0 | $0 |
| Other financing | $187.5M | $4.2M | $26.7M | $3.6M | $1.5M | $3.7M | $4.4M | $46,000 | $782,000 | −$525,000 | $124,000 | −$634,000 |
| Cash from financing activities | $187.5M | $4.2M | $26.7M | −$65.3M | $1.5M | $3.7M | $139.1M | $46,000 | $782,000 | −$525,000 | $124,000 | −$634,000 |
| Summary | ||||||||||||
| Net change in cash | $39.4M | −$14.7M | −$17.9M | $35.8M | $13.3M | $3.4M | $22.1M | $4.1M | −$11.0M | −$14.9M | −$86.1M | $73.4M |
| Cash at end of period | $117.7M | $78.4M | $93.0M | $110.9M | $75.2M | $61.9M | $58.5M | $36.4M | $32.3M | $43.3M | $58.2M | $144.2M |
| Free cash flow | $58.1M | −$62.5M | $41.8M | $14.2M | $4.7M | −$54.0M | −$45.3M | −$50.7M | −$52.2M | −$125.5M | −$76.0M | −$59.1M |
| Free cash flow margin | 34.2% | −49.2% | 32.2% | 8.6% | 4.1% | −66.0% | −60.5% | −80.6% | −96.5% | −303.3% | −168.7% | −159.4% |
| Capex / revenue | 13.1% | 17.4% | 14.5% | 0.1% | 0.2% | 14.4% | 12.8% | 13.0% | 22.2% | 15.6% | 12.3% | 0.0% |
| Operating cash flow / net income | — | — | — | 0.56 | — | — | — | — | — | — | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
TVTX cash generation
In fiscal 2025 (ended December 31, 2025), Travere Therapeutics generated $37.8 million of cash from operations and spent $58.2 million on capital expenditures, leaving free cash flow of -$20.4 million, −4.2% of revenue. Cash and equivalents rose by $34.5 million over the year.
Related: TVTX income statement, TVTX balance sheet. See the TVTX stock overview for the latest quote and news.
TVTX cash flow FAQ
What is Travere Therapeutics's free cash flow?
Travere Therapeutics's free cash flow was -$20.4 million in fiscal 2025: $37.8 million of operating cash flow minus $58.2 million of capital expenditures It was -$338.7 million a year earlier..
How much cash does Travere Therapeutics generate from operations?
Travere Therapeutics generated $37.8 million of cash from operating activities in fiscal 2025.
How much does Travere Therapeutics spend on capital expenditures?
Travere Therapeutics spent $58.2 million on capital expenditures in fiscal 2025, 11.9% of revenue, compared with $101.2 million the year before.